摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-甲基腺嘌呤 | 5142-22-3

中文名称
1-甲基腺嘌呤
中文别名
——
英文名称
1-methyladenine
英文别名
N1-Methyladenine;6-amino-1-methylpurine;1-methyl-1H-purin-6-ylamine;1-Methyl-1H-purin-6-ylamin;methyl adenine;1-methylpurin-6-amine
1-甲基腺嘌呤化学式
CAS
5142-22-3
化学式
C6H7N5
mdl
MFCD00010532
分子量
149.155
InChiKey
HPZMWTNATZPBIH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    300 °C
  • 沸点:
    260.22°C (rough estimate)
  • 密度:
    1.1798 (rough estimate)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.5
  • 重原子数:
    11.0
  • 可旋转键数:
    0.0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.166
  • 拓扑面积:
    69.62
  • 氢给体数:
    1.0
  • 氢受体数:
    4.0

安全信息

  • 危险品标志:
    Xn
  • 安全说明:
    S24/25
  • 危险类别码:
    R22
  • 海关编码:
    2933990090

SDS

SDS:d08629144c74e52166a4ef2457018116
查看
Name: 1-Methyladenine 99% Material Safety Data Sheet
Synonym: None Known
CAS: 5142-22-3
Section 1 - Chemical Product MSDS Name:1-Methyladenine 99% Material Safety Data Sheet
Synonym:None Known

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
5142-22-3 1-Methyladenine 99% 225-907-0
Hazard Symbols: None Listed.
Risk Phrases: None Listed.

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
Use agent most appropriate to extinguish fire.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Keep container closed when not in use. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use process enclosure, local exhaust ventilation, or other engineering controls to control airborne levels.
Exposure Limits CAS# 5142-22-3: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to minimize contact with skin.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: light yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: > 300 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H7N5
Molecular Weight: 149.15

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 5142-22-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-Methyladenine - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 5142-22-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 5142-22-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 5142-22-3 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

生物活性方面,1-Methyladenine是DNA中烷基化损伤的产物,可以通过氧化去甲基化的损伤逆转来修复。其主要靶点为人内源性代谢物。

反应信息

  • 作为反应物:
    描述:
    1-甲基腺嘌呤sodium hydroxide 作用下, 反应 4.0h, 以65%的产率得到6-甲基腺素
    参考文献:
    名称:
    Purines. XXIV. Methylation of N6-alkoxyadenines and N6-methyladenine.
    摘要:
    发现在 40°C 下,N6-甲氧基腺嘌呤 (3) 在 AcNMe2 中用过量的 Mel 进行甲基化,得到 3-甲基化产物 8(产率 17%)、9-甲基化产物 4(2%)、N6, 9-二甲基化产物5 (9%)、7, 9-二甲基化产物6 (27%)。 3,7-二甲基化产物7(10%),和N6,3-二甲基化产物9(11%)。用Mel对N6-苄氧基腺嘌呤(12)进行类似处理也得到几种产物的混合物,从中分离出7,9-二甲基化产物13(X=1),产率30%。 N6-甲基腺嘌呤 (17) 的类似甲基化,通过 Dimroth 型重排从 1-甲基腺嘌呤 (16) 制备,产率 65%。得到3-甲基化产物18(产率82%)、9-甲基化产物20(1.3%)、3, 7-二甲基化产物19(1.8%)和1, 9-二甲基化产物21(0.3%)。在相似的反应条件下进行甲基化时,18提供了9-甲基化产物22(产率15%)以及7-甲基化产物19(29%),20产生了22(17%)和21(11%)。讨论了 3 中六种甲基化产物和 17 中四种甲基化产物的可能途径。
    DOI:
    10.1248/cpb.31.4270
  • 作为产物:
    描述:
    7-(3-Methoxy-benzyl)-1-methyl-1,7-dihydro-purin-6-ylideneamine甲醇 为溶剂, 以65%的产率得到1-甲基腺嘌呤
    参考文献:
    名称:
    The photosolvolysis of N-arylmethyladenines. Photoremovable N-arylmethyl protective groups for N-containing compounds.
    摘要:
    DOI:
    10.1016/s0040-4039(00)97950-4
点击查看最新优质反应信息

文献信息

  • POLY(PHOSPHOESTERS) FOR DELIVERY OF NUCLEIC ACIDS
    申请人:TRANSLATE BIO, INC.
    公开号:US20200277446A1
    公开(公告)日:2020-09-03
    Disclosed are polymers comprising the moiety A, which is a moiety of formula I: and pharmaceutically acceptable salts thereof, wherein R, R 1 , R 2 , L, n1 and n2 are as defined herein. These polymers are useful for delivering nucleic acids to subject. These polymers and pharmaceutically acceptable compositions comprising such polymers and nucleic acids can be useful for treating various diseases, disorders and conditions.
    揭示了包含A基团的聚合物,该基团是化学式I的基团:及其药用可接受的盐,其中R、R1、R2、L、n1和n2如本文所定义。这些聚合物对于将核酸传递给受试者是有用的。这些聚合物和包含这些聚合物和核酸的药用可接受组合物可用于治疗各种疾病、疾病和症状。
  • [EN] CHEMOSELECTIVE THIOL-CONJUGATION WITH ALKENE OR ALKYNE-PHOSPHONAMIDATES<br/>[FR] CONJUGAISON CHIMIOSÉLECTIVE D'UN THIOL AVEC DES ALCÈNE- OU ALCYNE-PHOSPHONAMIDATES
    申请人:FORSCHUNGSVERBUND BERLIN EV
    公开号:WO2018041985A1
    公开(公告)日:2018-03-08
    Disclosed are novel conjugates and processes for the preparation thereof. A process for the preparation of alkene- or alkyne-phosphonamidates comprises the steps of (I) reacting a compound of formula (III), with an azide of formula (IV), to prepare a compound of formula (V), reacting a compound of formula (V) with a thiol-containing molecule of formula (VI), resulting in a compound of formula (VII).
    揭示了新颖的结合物和其制备方法。一种制备烯烃或炔烃酰胺酯的方法包括以下步骤:(I)将式(III)的化合物与式(IV)的叠氮化合物反应,制备出式(V)的化合物,将式(V)的化合物与式(VI)的含醇分子反应,得到式(VII)的化合物。
  • ADJUVANT IN THE FORM OF A LIPID-MODIFIED NUCLEIC ACID
    申请人:Hoerr Ingmar
    公开号:US20070280929A1
    公开(公告)日:2007-12-06
    The present invention relates to an immune-stimulating adjuvant in the form of a lipid-modified nucleic acid, optionally in combination with further adjuvants. The invention relates further to a pharmaceutical composition and to a vaccine, each containing an immune-stimulating adjuvant according to the invention, at least one active ingredient and optionally a pharmaceutically acceptable carrier and/or further auxiliary substances and additives and/or further adjuvants. The present invention relates likewise to the use of the pharmaceutical composition according to the invention and of the vaccine according to the invention for the treatment of infectious diseases or cancer diseases. Likewise, the present invention includes the use of the immune-stimulating adjuvant according to the invention in the preparation of a pharmaceutical composition for the treatment of cancer diseases or infectious diseases.
    本发明涉及一种免疫刺激佐剂,其形式为脂质修饰的核酸,可选地与其他佐剂结合。该发明还涉及一种含有根据本发明的免疫刺激佐剂、至少一种活性成分以及可选的药用载体和/或其他辅助物质和添加剂和/或其他佐剂的药物组合物和疫苗。本发明还涉及根据本发明的药物组合物和疫苗用于治疗传染病或癌症的用途。同样,本发明包括根据本发明的免疫刺激佐剂用于制备用于治疗癌症或传染病的药物组合物的用途。
  • Morpholino Nucleic Acid Derivatives
    申请人:Ueda Toshihiro
    公开号:US20130197220A1
    公开(公告)日:2013-08-01
    The present invention provides a useful morpholino nucleic acid derivative for synthesizing a morpholino nucleic acid oligomer. The present invention provides a compound represented by the following general formula (1) or a salt thereof. Here, R 1 represents hydrogen, trityl and so on. R 2 represents an amide or an imine. R 3 represents a hydroxy group which may be protected by trialkylsilyl and so on, or a group represented by the following general formula (5): (wherein X represents O or S, Y represents dialkylamino or alkoxy, and Z represents chlorine).
    本发明提供了一种用于合成吗啉核酸寡聚体的有用吗啉核酸衍生物。本发明提供了以下一般式(1)或其盐所代表的化合物。 在这里,R1代表氢、三苯甲基等。 R2代表酰胺或亚胺。 R3代表一个羟基,可能被三烷基基等保护,或者由以下一般式(5)所代表的基团: (其中X代表O或S,Y代表二烷基基或烷氧基,Z代表)。
  • [EN] CATIONIC LIPIDS COMPRISING AN HYDROXY MOIETY<br/>[FR] LIPIDES CATIONIQUES COMPRENANT UNE FRACTION HYDROXY
    申请人:TRANSLATE BIO INC
    公开号:WO2020257611A1
    公开(公告)日:2020-12-24
    Disclosed are lipids which are compounds of Formula I. Lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.
    本文披露的是化合物I的脂质。本文提供的脂质可用于传递和表达mRNA和编码蛋白,例如作为脂质体传递载体的组分,因此可用于治疗与一种或多种蛋白质缺乏相关的各种疾病、紊乱和症状。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
hnmr
mass
cnmr
ir
raman
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台